Keyword: Kymera Therapeutics
The public markets have been receptive to early-stage biotechs but will the IPO remain open? We asked our Fierce 15 winners what they thought.
Plexium is launching with $28 million to build its platform and a pipeline of drugs that target the enzymes drive recognition of protein targets.
Carmen Bozic, M.D., Vertex's new head of global medicines development and medical affairs, will take over the CMO post April 1.
Loh joins the computational chemistry specialist after a two-year stint at Kymera Therapeutics.
Looking to harness the body’s protein degradation processes, Kymera has raised more than $150 million for its pipeline of small molecules, led by a program targeting IRAK4, a protein involved in disease-signaling pathways.
In mice, Kymera's lead drug promoted tumor regression, both on its own and in combination with BTK inhibitor Imbruvica.
The early-stage deal features more than $1 billion in milestones tied to the success of six programs.
Kymera Therapeutics raised $65 million in series B funding that will support the clinical development of its lead protein degradation program.
Jared Gollob, M.D., is joining Kymera Therapeutics, a startup focused on protein degradation.
Six months after getting off its series A, Kymera Therapeutics has nabbed a deal with GlaxoSmithKline, although exact details are under wraps.
